AntBio is a life science company that integrates three core sub-brands—Absin (tools for life science founded in 2004), Starter (offers antibodies, proteins, and assay kits and was founded in 2021), and UA-BIO (recombinant protein pioneer founded in 2018)—into a unified platform for research and diagnostic reagents. Its stated mission is to fuel research and feed discovery by providing comprehensive, high-quality life science reagents and solutions, enabling scientists and researchers worldwide to accelerate advances in basic research, drug development, and clinical diagnosis.

The company focuses on delivering full-range and high-quality reagent tools covering research-grade antibodies, recombinant proteins, assay kits, and customized services for diverse applications in the life sciences. AntBio’s vision is to become a global leader in life science reagents, with an emphasis on supporting work across the continuum from fundamental biology to translational and clinical research.

A core AntBio technology is its proprietary S-RMab^® single B cell antibody recombination platform, which is designed to produce recombinant antibodies with high specificity, high affinity (including picomolar-level affinity), and strong batch-to-batch consistency. This platform underpins a portfolio that includes IHC antibodies, flow antibodies, post-translational modification (PTM) antibodies, and paired antibodies.

Quality management is formalized through multiple certifications, including ISO9001, ISO13485, and EU 98/79/EC, which are applied across product lines. According to the company, numerous products have been validated in more than 10,000 cumulative scientific publications, contributing to its reputation within the global life science research community.

AntBio’s product ecosystem is comprehensive and covers the entire lifecycle of life science research. This ecosystem ranges from antibodies, proteins, and ELISA kits to organoid culture tools, spatial biology solutions, drug discovery solutions, and raw materials for in vitro diagnostics (IVD). Within this framework, the company positions its offerings as cost-effective while aiming to maintain performance that is equivalent or superior to that of established international brands, supported by external certifications and literature citations.

The company organizes its portfolio into six major categories. The first is ELISA kits, which includes OneStep ELISA products with an approximately 1-hour workflow, ultra-high sensitivity (down to 0.13 pg/ml), and a wide dynamic range (up to 100-fold). In addition, AntBio offers conventional ELISA kits covering over 2,000 targets, with more than 800 published papers citing these products.

The second category is cell and organoid culture products. This includes ready-to-use organoid culture kits for more than 17 organoid types—such as intestinal, liver, and lung—reporting higher than 80% success rates, time-saving protocols with primary culture steps that can be completed in about 1 hour, and full-process technical support. Complementing these kits are self-developed cytokines with stated purity greater than 95%, endotoxin levels below 0.1 EU/µg, and verified biological activity.

The third category is spatial biology solutions. Here, AntBio offers IHC primary antibodies and matched IHC secondary detection kits, as well as multiplex IHC (mIHC) kits with 2–10 color options. These mIHC kits incorporate anti-photobleaching technology, polymer-HRP for higher sensitivity, and compatibility with both FFPE and fresh-frozen tissue samples.

The fourth category is proteomics solutions, focusing particularly on PTM analysis. The company supplies PTM antibodies, including pan-modification and site-specific mini-antibody sets for modifications such as methylation, acetylation, and lactylation. These reagents have high specificity, high batch consistency, and validation across multiple sample types. For mass spectrometry workflows, AntBio also provides MS-grade trypsin and other enzymes for sample pretreatment.

The fifth category encompasses drug discovery tools. This includes target proteins and enzymes such as PD-1, PD-L1, and HER2, aimed at applications in antibody drug development, antibody–drug conjugates (ADCs), CAR-T therapies, and related modalities. Additional offerings in this category include TR-FRET binding kits, HICA assay kits, OneStep ELISA kits adapted for screening, UA-Glo ADP kinase assay, cell viability assays, reporter gene systems, and FACS/MACS-related products. These tools are intended for in vitro drug screening and verification, internalization assays, and the development and evaluation of anti-payload and anti-idiotypic antibodies for macromolecular drugs.

The final category focuses on IVD raw materials. AntBio provides CDx/IHC antibodies and paired antibodies for tumor markers, infectious disease targets, and neurology-related markers that meet clinical diagnostic quality standards. These materials are designed for use by diagnostic manufacturers and laboratories that require reagents aligned with regulatory and performance requirements.

AntBio aspires to become a transformative force in global life science by serving as a trusted partner to researchers, biopharma companies, and diagnostic providers worldwide, regardless of their size or location. The company is also focused on reducing barriers of accessibility and efficiency by making high-quality antibodies, proteins, and kits available to labs in emerging markets and smaller research groups, with the aim that promising scientific ideas are not limited by the cost or availability of reagents.

AntBio is especially excited about the synergistic integration of its three core platforms—antibody development, protein development, and quality validation—and how they have supercharged key products. These platforms have improved IHC antibodies, flow antibodies, PTM antibodies, and paired antibodies by increasing their specificity and consistency. OneStep ELISA kits have also advanced to provide faster, more reliable results through rigorous cross-validation. This approach builds a cohesive ecosystem where daily research tools are more efficient and trustworthy, allowing researchers to prioritize breakthroughs over reagent limitations.